Initiation of Phase 2B Study Follows Quickly After FDA Grants RMAT Designation for Knee OA MARIETTA, Ga. , March 28, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that the first patient has been
MARIETTA, Ga. , March 26, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, announced today that it will participate in the 17th Annual Needham Healthcare Conference in New York on Wednesday, March 28, 2018 .
Patients Experienced Clinically Meaningful Reduction in Pain AmnioFix Injectable Achieves Primary and Secondary Efficacy Endpoints Statistically Significant Difference in Pain and Function Compared to Placebo MARIETTA, Ga. , March 26, 2018 /PRNewswire/ -- MiMedx Group, Inc.
Continues to Cooperate with Regulatory Agencies MARIETTA, Ga. , March 15, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced its expectation for first quarter of 2018 revenue to exceed the $92 million
MARIETTA, Ga. , March 9, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that the U.S. Food and Drug Administration ( FDA ) has granted MiMedx's micronized amniotic tissue, AmnioFix® Injectable, the
MARIETTA, Ga. , March 2, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today received written notification from the NASDAQ Stock Market that the Company is no longer in compliance with the NASDAQ Listing Rules
MARIETTA, Ga. , Feb. 27, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today stated that the Company is not aware of any investigation of MiMedx by the Department of Justice (DOJ).
MARIETTA, Ga. , Feb. 21, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, announced today that it will host a live broadcast of the Company's conference call to provide an operational update on Friday, February 23,
MARIETTA, Ga. , Feb. 20, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it will postpone the release of its financial results, as well as the filing of its Form 10-K, for the year ended
MARIETTA, Ga. , Jan. 25, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare,
